These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17652619)

  • 1. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
    Bürkle A; Niedermeier M; Schmitt-Gräff A; Wierda WG; Keating MJ; Burger JA
    Blood; 2007 Nov; 110(9):3316-25. PubMed ID: 17652619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells.
    Chunsong H; Yuling H; Li W; Jie X; Gang Z; Qiuping Z; Qingping G; Kejian Z; Li Q; Chang AE; Youxin J; Jinquan T
    J Immunol; 2006 Nov; 177(10):6713-22. PubMed ID: 17082584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.
    Hu C; Xiong J; Zhang L; Huang B; Zhang Q; Li Q; Yang M; Wu Y; Wu Q; Shen Q; Gao Q; Zhang K; Sun Z; Liu J; Jin Y; Tan J
    Cell Mol Immunol; 2004 Aug; 1(4):280-94. PubMed ID: 16225771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function.
    Schaerli P; Willimann K; Lang AB; Lipp M; Loetscher P; Moser B
    J Exp Med; 2000 Dec; 192(11):1553-62. PubMed ID: 11104798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia.
    Qiuping Z; Jie X; Youxin J; Qun W; Wei J; Chun L; Jin W; Yan L; Chunsong H; Mingzhen Y; Qingping G; Qun L; Kejian Z; Zhimin S; Junyan L; Jinquan T
    Oncogene; 2005 Jan; 24(4):573-84. PubMed ID: 15580304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection.
    Cagigi A; Mowafi F; Phuong Dang LV; Tenner-Racz K; Atlas A; Grutzmeier S; Racz P; Chiodi F; Nilsson A
    Blood; 2008 Dec; 112(12):4401-10. PubMed ID: 18780835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.
    López-Giral S; Quintana NE; Cabrerizo M; Alfonso-Pérez M; Sala-Valdés M; De Soria VG; Fernández-Rañada JM; Fernández-Ruiz E; Muñoz C
    J Leukoc Biol; 2004 Aug; 76(2):462-71. PubMed ID: 15155773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF.
    Harrer C; Otto F; Pilz G; Haschke-Becher E; Trinka E; Hitzl W; Wipfler P; Harrer A
    Fluids Barriers CNS; 2021 Aug; 18(1):40. PubMed ID: 34446066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
    Sivina M; Xiao L; Kim E; Vaca A; Chen SS; Keating MJ; Ferrajoli A; Estrov Z; Jain N; Wierda WG; Huang X; Chiorazzi N; Burger JA
    Leukemia; 2021 Jun; 35(6):1610-1620. PubMed ID: 33087831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity.
    Wong CK; Wong PT; Tam LS; Li EK; Chen DP; Lam CW
    J Clin Immunol; 2010 Jan; 30(1):45-52. PubMed ID: 19774453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.
    Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Ransohoff RM; Ness JM; Colliver JA
    J Neuroimmunol; 2012 Feb; 243(1-2):81-8. PubMed ID: 22264765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
    Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
    Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
    Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
    Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The healing myocardium mobilizes a distinct B-cell subset through a CXCL13-CXCR5-dependent mechanism.
    Heinrichs M; Ashour D; Siegel J; Büchner L; Wedekind G; Heinze KG; Arampatzi P; Saliba AE; Cochain C; Hofmann U; Frantz S; Campos Ramos G
    Cardiovasc Res; 2021 Nov; 117(13):2664-2676. PubMed ID: 34048536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.
    Biswas S; Sengupta S; Roy Chowdhury S; Jana S; Mandal G; Mandal PK; Saha N; Malhotra V; Gupta A; Kuprash DV; Bhattacharyya A
    Breast Cancer Res Treat; 2014 Jan; 143(2):265-76. PubMed ID: 24337540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
    Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
    Blood; 2012 May; 119(20):4708-18. PubMed ID: 22474251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma.
    Vermi W; Lonardi S; Bosisio D; Uguccioni M; Danelon G; Pileri S; Fletcher C; Sozzani S; Zorzi F; Arrigoni G; Doglioni C; Ponzoni M; Facchetti F
    J Pathol; 2008 Nov; 216(3):356-64. PubMed ID: 18792075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics.
    Sáez de Guinoa J; Barrio L; Mellado M; Carrasco YR
    Blood; 2011 Aug; 118(6):1560-9. PubMed ID: 21659539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases.
    Aust G; Sittig D; Becherer L; Anderegg U; Schütz A; Lamesch P; Schmücking E
    Eur J Endocrinol; 2004 Feb; 150(2):225-34. PubMed ID: 14763921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.